Free Trial
NASDAQ:CYCC

Cyclacel Pharmaceuticals (CYCC) Stock Price, News & Analysis

Cyclacel Pharmaceuticals logo
$3.31 -0.40 (-10.78%)
Closing price 04:00 PM Eastern
Extended Trading
$3.58 +0.28 (+8.31%)
As of 05:27 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Cyclacel Pharmaceuticals Stock (NASDAQ:CYCC)

Key Stats

Today's Range
$3.27
$3.65
50-Day Range
$0.23
$84.96
52-Week Range
$3.08
$597.60
Volume
132,768 shs
Average Volume
102,009 shs
Market Capitalization
$5.25 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
Hold

Company Overview

Cyclacel Pharmaceuticals Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
27th Percentile Overall Score

CYCC MarketRank™: 

Cyclacel Pharmaceuticals scored higher than 27% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Cyclacel Pharmaceuticals is 0.00, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Cyclacel Pharmaceuticals is 0.00, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Read more about Cyclacel Pharmaceuticals' valuation and earnings.
  • Percentage of Shares Shorted

    0.08% of the float of Cyclacel Pharmaceuticals has been sold short.
  • Short Interest Ratio / Days to Cover

    Cyclacel Pharmaceuticals has a short interest ratio ("days to cover") of 0, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Cyclacel Pharmaceuticals has recently decreased by 99.78%, indicating that investor sentiment is improving significantly.
  • Percentage of Shares Shorted

    0.08% of the float of Cyclacel Pharmaceuticals has been sold short.
  • Short Interest Ratio / Days to Cover

    Cyclacel Pharmaceuticals has a short interest ratio ("days to cover") of 0, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Cyclacel Pharmaceuticals has recently decreased by 99.78%, indicating that investor sentiment is improving significantly.
  • News Sentiment

    Cyclacel Pharmaceuticals has a news sentiment score of 0.48. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 1.01 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 5 news articles for Cyclacel Pharmaceuticals this week, compared to 1 article on an average week.
  • Search Interest

    6 people have searched for CYCC on MarketBeat in the last 30 days. This is an increase of 200% compared to the previous 30 days.
  • MarketBeat Follows

    1 people have added Cyclacel Pharmaceuticals to their MarketBeat watchlist in the last 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Cyclacel Pharmaceuticals insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    96.90% of the stock of Cyclacel Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    Only 23.58% of the stock of Cyclacel Pharmaceuticals is held by institutions.

  • Read more about Cyclacel Pharmaceuticals' insider trading history.
Receive CYCC Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Cyclacel Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

CYCC Stock News Headlines

Cyclacel Pharmaceuticals, Inc. (CYCCP) - Yahoo Finance
3..2..1.. AI 2.0 ignition (don’t sleep on this)
I just put together an urgent new presentation that you need to see right away. In short: I believe we are mere days away from a critical announcement from a key tech leader… One that will officially ignite “AI 2.0” – and potentially send a whole new class of stocks soaring.
See More Headlines

CYCC Stock Analysis - Frequently Asked Questions

Cyclacel Pharmaceuticals' stock was trading at $90.24 at the beginning of 2025. Since then, CYCC shares have decreased by 96.3% and is now trading at $3.37.

Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) issued its quarterly earnings results on Wednesday, April, 2nd. The biotechnology company reported ($79.20) EPS for the quarter, missing analysts' consensus estimates of ($69.60) by $9.60. The biotechnology company had revenue of $0.01 million for the quarter, compared to analysts' expectations of $0.01 million.

Cyclacel Pharmaceuticals's stock reverse split on the morning of Monday, July 7th 2025.The 1-15 reverse split was announced on Wednesday, July 2nd 2025. The number of shares owned by shareholders was adjusted after the market closes on Thursday, July 3rd 2025. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split.

Shares of CYCC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Cyclacel Pharmaceuticals investors own include NVIDIA (NVDA), Meta Platforms (META), GE Aerospace (GE), Broadcom (AVGO), Advanced Micro Devices (AMD), CymaBay Therapeutics (CBAY) and Arista Networks (ANET).

Company Calendar

Last Earnings
4/02/2025
Record date for 5/1 Dividend
4/29/2025
Ex-Dividend for 5/1 Dividend
4/29/2025
Dividend Payable
5/01/2025
Today
7/14/2025
Next Earnings (Estimated)
8/13/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - BIOMED/GENE
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:CYCC
CIK
1130166
Employees
14
Year Founded
N/A

Profitability

EPS (Trailing Twelve Months)
($839.58)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$11.21 million
Net Margins
N/A
Pretax Margin
-55,535.71%
Return on Equity
-3,648.09%
Return on Assets
-155.99%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
5.60
Quick Ratio
5.60

Sales & Book Value

Annual Sales
$14 thousand
Price / Sales
381.53
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
($58.87) per share
Price / Book
-0.06

Miscellaneous

Outstanding Shares
1,585,000
Free Float
773,000
Market Cap
$5.34 million
Optionable
Optionable
Beta
0.03

Social Links

5G Stocks: The Path Forward is Profitable Cover

Enter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

This page (NASDAQ:CYCC) was last updated on 7/14/2025 by MarketBeat.com Staff
From Our Partners